Fig. 1: Examples of a PD-L1 expression in different tumor types using different PD-L1 immunohistochemistry (IHC) assay. | Modern Pathology

Fig. 1: Examples of a PD-L1 expression in different tumor types using different PD-L1 immunohistochemistry (IHC) assay.

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Fig. 1

a Hematoxylin and Eosin (H&E) stain of a non-small cell lung carcinoma (NSCLC) case with all tumor cells staining in the corresponding. b DAKO 22C3 IHC giving it a tumor proportion score (TPS) of 100. Next are examples of two head and neck squamous cell carcinoma (HNSCC) with different biomarker status based on a tumor proportion score (TPS) cutoff of 1 and combined positive score (CPS) cutoff of 1. c H&E stain of a HNSCC case with no tumor cells but with immune staining in the corresponding. d DAKO 22C3 IHC giving it a negative status with the TPS score (TPS < 1) but positive status with the CPS score (CPS ≥ 1). e H&E stain of a HNSCC case with no immune cell but with tumor cell staining in the corresponding. f DAKO 22C3 IHC giving it a positive status for both the CPS score (CPS ≥ 1) and the TPS score (TPS ≥ 1). g The last H&E is of a triple negative breast carcinoma case that was stained with a (h) SP142 CDx IHC and shows the immune cells staining with a dark, granular punctate pattern. This case had a tumor-infiltrating immune cell (IC) score ≥ 1, which is considered positive with the SP142 CDx assay for TNBC. All digital images are at ×200 magnification.

Back to article page